| First Author | Carrasco DR | Year | 2006 |
| Journal | Cancer Cell | Volume | 9 |
| Issue | 5 | Pages | 379-90 |
| PubMed ID | 16697958 | Mgi Jnum | J:108872 |
| Mgi Id | MGI:3625221 | Doi | 10.1016/j.ccr.2006.03.028 |
| Citation | Carrasco DR, et al. (2006) The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans. Cancer Cell 9(5):379-90 |
| abstractText | Histiocytic sarcoma (HS) is a rare malignant proliferation of histiocytes of uncertain molecular pathogenesis. Here, genetic analysis of coincident loss of Pten and Ink4a/Arf tumor suppressors in the mouse revealed a neoplastic phenotype dominated by a premalignant expansion of biphenotypic myelolymphoid cells followed by the development of HS. Pten protein loss occurred only in the histiocytic portion of tumors, suggesting a stepwise genetic inactivation in the generation of HS. Similarly, human HS showed genetic or epigenetic inactivation of PTEN, p16(INK4A), and p14(ARF), supporting the relevance of this genetically engineered mouse model of HS. These genetic and translational observations establish a cooperative role of Pten and Ink4a/Arf in the development of HS and provide mechanistic insights into the pathogenesis of human HS. |
